Compare Medpace Holdings Inc (MEDP) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Impinj Inc — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Impinj Inc trades at $189.56 (market cap $5.60B). The key difference: Medpace Holdings Inc is far larger — about 3× Impinj Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Impinj Inc for 22 Days on average.
| MEDP | PI | |
|---|---|---|
Market Cap | $16.82B | $5.60B |
Volume | 223,093 | 9,929 |
Sector | Health | Technology |
52-Week High | $630.19 | $241.91 |
52-Week Low | $393.42 | $91.34 |
Typical Hold Time | 14 Days | 22 Days |
Enterprise Value | $16.44B | $5.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Impinj (PI) trades at $189.16, down 0.98% on the day, with strong analyst support (16 buy ratings, 0 sell) and a consensus price target of $178.83. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026, though profitability remains negative with a -7.26% net income margin. Recent news highlights include upcoming Q3 earnings and CFO stock sales.
While technical indicators and analyst sentiment are positive, fundamental challenges persist with negative ROE and high valuation multiples. The company's RAIN RFID technology presents growth opportunities in logistics, but investors should weigh execution risks against the bullish consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
